Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7200163 | 0.85 | SPHK1 (0.35) | SPHK1HCRTR2ABCB1 | |
| SCHEMBL15910576 | 0.82 | SPHK1 (0.40) | SPHK1NR1H2HCRTR2ABCB1USP2 | |
| SCHEMBL15910575 | 0.82 | SPHK1 (0.40) | SPHK1NR1H2HCRTR2ABCB1USP2 | |
| SCHEMBL23336182 | 0.82 | SPHK1 (0.40) | SPHK1NR1H2HCRTR2ABCB1USP2 | |
| SCHEMBL18360122 | 0.82 | SPHK1 (0.40) | SPHK1NR1H2HCRTR2ABCB1USP2 | |
| SCHEMBL7207475 | 0.79 | USP2 (0.34) | SPHK1HCRTR2USP2SMN1; SMN2BRD4 | |
| SCHEMBL15156601 | 0.79 | USP2 (0.34) | SPHK1HCRTR2USP2SMN1; SMN2BRD4 | |
| SCHEMBL10273026 | 0.78 | SPHK1 (0.38) | SPHK1NR1H2HCRTR2USP2SMN1; SMN2 | |
| SCHEMBL7287745 | 0.78 | SPHK1 (0.34) | SPHK1NR1H2HCRTR2 | |
| SCHEMBL9556672 | 0.78 | SPHK1 (0.33) | SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087831-A1 | 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-08 | — | — | US | disclosed |
| EP-1234834-A1 | 1,3,4-OXADIAZOLIN-2-ONE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087831-A1 | 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient | SERPINB1, ELANE, MMP8 | SPHK1 3552/4885NR1H2 195/4885HCRTR2 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.